Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab vs Conventional Immunosuppression in Uveitis
NCT03828019Phase 3Completed
- Sponsor
- Johns Hopkins Center for Clinical Trials and Evidence Synthesis
- Start
- Sep 2019
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of adalimumab in intermediate uveitis (IU), posterior uveitis, panuveitis, sponsored by Johns Hopkins Center for Clinical Trials and Evidence Synthesis. Started Sep 2019; status: completed.
02
Drugs
03
Conditions
intermediate uveitis (IU)posterior uveitispanuveitis
Beyond the preview
Go deeper on NCT03828019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03828019.